ClinicalTrials.gg
CompletedNCT03319953Updated Mar 19, 2021Results posted

A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia

A Phase 2 interventional study of TAK-041 and Placebo in Stable Schizophrenia, sponsored by Neurocrine Biosciences. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-03-19.

Sponsored by Neurocrine Biosciences · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 16 studies in Schizophrenia by Neurocrine Biosciences — 6 open to participants now, 6 under way, 4 of them phase 3. Schizophrenia · Neurocrine Biosciences.

Enrollment
15th of 16
23 · median 165
Started
2017
the only one that year
Phase 2
6 of 16
1 open now
Registered
3rd of 16
by date

Among the 16 studies in Schizophrenia by Neurocrine Biosciences, this one is the 15th largest by enrollment, is the only one that started in 2017, is one of 6 in phase 2, and was the 3rd registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 16 studies in Schizophrenia by Neurocrine Biosciences are open now, in 7 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Schizophrenia by Neurocrine Biosciences, or all of them as a file.
02

Study summary

The purpose of the study is to determine whether motivation/reward deficits observed in schizophrenia are attenuated and whether cognitive impairment associated with schizophrenia is improved by add-on TAK-041 administration to antipsychotics in participants with stable schizophrenia.

Read the detailed description

The drug being tested in this study is called TAK-041. TAK-041 is being tested to treat people who have stable schizophrenia. This study will look whether motivation/reward deficits observed in schizophrenia are attenuated and whether cognitive impairment associated with schizophrenia is improved in people who take TAK-041 in addition to standard care.

The study will enroll approximately 32 patients. Participants will be randomly assigned (by chance, like flipping a coin) in 1:1 ratio to one of the two treatment sequences -which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need) to receive either TAK-041 40 mg or Placebo first and then will be crossed over to receive the opposite Intervention.

All participants will be asked to take oral suspension on Day 1 of each Period. There will be a wash-out Period of 35 days between the dosing days in Period 1 and 2.

This single-center trial will be conducted in the United Kingdom. The overall time to participate in this study is approximately 126 to 154 days. Participants will make multiple visits to the clinic plus a final visit 77 days after receiving their last dose of drug for a follow-up assessment.

03

Conditions studied

  • Stable Schizophrenia

Browse trials for

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is on a stable dose of antipsychotics for at least 2 months as documented by medical history and assessed by site staff (other than those on the excluded medication list).
  2. Meets schizophrenia criteria as defined by the (DSM-5) by the Mini International Neuropsychiatric Interview (MINI).
  3. Have Positive and Negative Syndrome Scale (PANSS) total score less than or equal to (\<=) 90 and PANSS Negative Symptom Factor Score ([NSFS]; Sum of PANSS N1, N2, N3, N4, N6, G7, and G16) greater than or equal to (>=) 15 at screening and baseline (Day -1).
  4. Has stable Screening and baseline (Day-1) PANSS and NSFS total scores (less than [\<] 20 percent [%] change).
  5. Have had a structural brain magnetic resonance imaging (MRI) within the preceding year or during screening indicating no concerning structural brain abnormalities or other abnormalities that would interfere with interpretation of functional brain imaging results.

Exclusion criteria

Exclusion Criteria:

  1. Has a history of cancer ().
  2. Has a positive alcohol and/ or positive drug screen at Screening or Day -1.
  3. Is positive for surface antigen (HBsAg), (HCV) antibody, or (HIV) antibody/antigen (confirmatory testing is allowed; most sensitive test should take precedence).
  4. Had major surgery, or donated or lost 1 unit of blood (approximately 500 milliliters [mL]) within 4 weeks prior to the pretrial/Screening Visit.
  5. Has abnormal Screening or baseline laboratory values (> [ULN] for the respective serum chemistries) of (ALT), aspartate aminotransferase (AST), total (TBILI), alkaline phosphatase (ALP), γ-glutamyl transferase (GGT) confirmed upon repeat testing, 5'-nucleotidase (Screening only), and/or abnormal urine osmolality, confirmed upon repeat testing.
  6. Meets criteria for substance use disorder or history of alcohol abuse within 1 month prior to Screening Visit.
  7. Has a history of claustrophobia or inability to tolerate mock scanner environment during habituation/screening session.
  8. Fulfills any of the MRI on the site standard radiography screening document.
  9. Has a history in the last year from the randomization visit or is currently receiving treatment with clozapine.
  10. Has a current diagnosis of a significant psychiatric illness other than schizophrenia, per DSM-5 and is in an acute phase or episode.
  11. Has a risk of suicide according to the investigator's clinical judgment (example, per C-SSRS positive answers on questions 4 or 5 or has made a suicide attempt within 6 months prior to screening visit).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Treatment Sequence 1: TAK-041 40 mg/Placebo + Antipsychotics

    TAK-041 40 milligram (mg), suspension, orally on Day 1 of Treatment Period 1, followed by 35 day Wash-out Period, followed by TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 2. All participants received a stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.

    Drug: TAK-041 · Drug: Placebo · Drug: Second Generation Antipsychotics (SGA)

  • Experimental
    Treatment Sequence 2: Placebo/TAK-041 40 mg + Antipsychotics

    TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 1, followed by 35 days Wash-out Period, followed by TAK-041 40 mg, suspension, orally on Day 1 of Treatment Period 2. All participants received a stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.

    Drug: TAK-041 · Drug: Placebo · Drug: Second Generation Antipsychotics (SGA)

  • Experimental
    Treatment Sequence 3: TAK-041 160 mg/Placebo + Antipsychotics

    TAK-041 160 mg, suspension, orally on Day 1 of Treatment Period 1, followed by 35 days Wash-out Period, followed by TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 2. All participants received stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.

    Drug: TAK-041 · Drug: Placebo · Drug: Second Generation Antipsychotics (SGA)

  • Experimental
    Treatment Sequence 4: Placebo/TAK-041 160 mg + Antipsychotics

    TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 1, followed by 35 days Wash-out Period, followed by TAK-041 160 mg, suspension, orally on Day 1 of Treatment Period 2. All participants received stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.

    Drug: TAK-041 · Drug: Placebo · Drug: Second Generation Antipsychotics (SGA)

Interventions

  • TAK-041 suspension

  • DrugPlacebo

    TAK-041 placebo-matching suspension

  • DrugSecond Generation Antipsychotics (SGA)

    Second generation antipsychotics included risperidone, paliperidone, iloperidone, quetiapine, olanzapine, ziprasidone, asenapine and lurasidone.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Brief Assessment of Cognition in Schizophrenia (BACS) Composite Score at Second Testing After TAK-041 Administration

    BACS is a reliable and sensitive measure of cognitive function in schizophrenia. The BACS consists of items across six subtests: Verbal Memory, Digit Sequencing, Token Motor, Verbal Fluency, Symbol Coding, and Tower of London. The subtest scale scores were used to compute a composite BACS t-score of 50 (20) is the mean (standard deviation) of a relevant index population. Higher values indicate better performance. Bayesian normal linear model was used for analysis.

    Time frame: Baseline (Day -1) and Day 14

  2. Blood-Oxygen-Level-Dependent (BOLD) Signal in the Average Ventral Striatum (VS) Region of Interest (ROI) Activation in the Monetary Incentive Delay (MID) Reward Task at First Testing After TAK-041 Administration

    Blood-oxygen-level-dependent imaging, or BOLD-contrast imaging, is a method used in functional magnetic resonance imaging (fMRI) to observe different areas of the brain or other organs, which are found to be active at any given time. The MID task is a reward anticipation paradigm that robustly engages the VS, a key area associated with coding incentive reward. Dysfunctional processing of reward information is associated with motivational impairments in schizophrenia. Motivational impairment is a key aspect of negative symptoms, and has been associated with reduced activity in the VS. Any change in BOLD signal that comes in fMRI is reported.

    Time frame: Day 1

Secondary outcomes

  1. Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: From the first dose of study drug up to 77 days after last dose of study drug (Up to Day 154)

  2. Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post Dose

    Clinical Laboratory parameters included tests for chemistry, hematology and urinalysis. Markedly abnormal values during treatment period were categorized as: alanine aminotransferase (ALT)\>3.0 U/L\*upper limit of normal(ULN),albumin\<25 g/L\*lower limit of normal(LLN), alkaline phosphatase \>3.0 U/L\*ULN, aspartate aminotransferase \>3.0 U/L\*ULN, bilirubin \>34.2 umol/L\*ULN, calcium \<1.75 mmol/L, \>2.88 mmol/L, chloride \<75 mmol/L, \>126 mmol/L, creatinine \>177umol/L, gamma glutamyl transferase \>3 U/L\*ULN, glucose \<2.8 mmol/L, \>19.4 mmol/L, potassium\<3 mmol/L, \>6 mmol/L, sodium \<130 mmol/L, \>150 mmol/L,Urea \<130 mmol/L, erythrocytes \<0.8\*LLN \>1.2\*ULN, hematocrit \<0.8\*LLN, \>1.2\*ULN, hemoglobin \<0.8 g/L\*LLN, \>1.2 g/L\*ULN, leukocytes \<0.5 (10\^9/L)\*LLN, \>1.5 (10\^9/L)\*ULN, platelets \<75(10\^9/L), \>600(10\^9/L).

    Time frame: From the first dose of study drug up to 77 days after last dose of study drug (Up to Day 154)

  3. Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements At Least Once Post Dose

    Vital signs included oral body temperature measurement, supine and standing blood pressure, respiration rate, and pulse. Pulse and blood pressure were measured after 5 minutes supine and again at 1 and 3 minutes after standing. The markedly abnormal value (MAV) criteria for vital signs included systolic blood pressure \< 85 mmHg, \> 180 mmHg; diastolic blood pressure \< 50 mmHg, \> 110 mmHg; pulse \< 50 beats/min, \> 120 beats/min; temperature \< 35.6 C \> 37.7 C.

    Time frame: From the first dose of study drug up to 77 days after last dose of study drug (Up to Day 154)

  4. Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) at Least Once Post Dose

    The markedly abnormal value (MAV) criteria for 12-lead ECG parameters included ECG Mean Heart Rate \< 50 beats/min, \> 120 beats/min; PR Interval, Aggregate \<= 80 msec, \>= 200 msec; QRS Duration, Aggregate \<= 80 msec, \>= 180 msec; QTcB Interval, Aggregate \<= 300 msec, \>= 500 msec OR (\>= 30 msec change from baseline and \>= 450 msec); QTcF Interval, Aggregate \<= 300 msec, \>= 500 msec OR (\>= 30 msec change from baseline and \>= 450 msec).

    Time frame: From the first dose of study drug up to 77 days after last dose of study drug (Up to Day 154)

  5. Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS)

    Treatment-emergent suicidal ideation (SI) or suicidal behavior (SB) compared to baseline will be measured by an increase in suicidal ideation category (1-5 on the C-SSRS) or suicidal behavior category (6-10 on the C-SSRS) during treatment from the maximum suicidal ideation/behavior category at baseline, or any suicidal ideation/behavior during treatment if there is none at baseline. C-SSRS is used to assess whether participant experienced suicidal ideation (1: wish to be dead; 2: non-specific active suicidal thoughts; 3: active suicidal ideation with any methods (not plan) without intent to act; 4: active suicidal ideation with some intent to act, without specific plan; 5: active suicidal ideation with specific plan and intent) and suicidal behavior (6: actual attempt; 7: interrupted attempt; 8: aborted attempt; 9: preparatory acts or behavior; 10: suicidal behavior).

    Time frame: Baseline (Day -1) and Days 14, 35 and 77

07

Results

Posted Feb 9, 2021

Participant flow

Participants took part in the study at single investigative sites in United Kingdom from 21 December 2017 to 06 November 2019.

Period 1 (Day 1 to 14)
Participant flow — Period 1 (Day 1 to 14)
MilestoneTreatment Sequence 1: TAK-041 40 mg/Placebo + AntipsychoticsTreatment Sequence 2: Placebo/TAK-041 40 mg + AntipsychoticsTreatment Sequence 3: TAK-041 160 mg/Placebo + AntipsychoticsTreatment Sequence 4: Placebo/TAK-041 160 mg + Antipsychotics
Started3497
Completed3497
Not completed0000
Washout Period (Day 15 to 49)
Participant flow — Washout Period (Day 15 to 49)
MilestoneTreatment Sequence 1: TAK-041 40 mg/Placebo + AntipsychoticsTreatment Sequence 2: Placebo/TAK-041 40 mg + AntipsychoticsTreatment Sequence 3: TAK-041 160 mg/Placebo + AntipsychoticsTreatment Sequence 4: Placebo/TAK-041 160 mg + Antipsychotics
Started3497
Completed3497
Not completed0000
Period 2 (Day 49 to 154)
Participant flow — Period 2 (Day 49 to 154)
MilestoneTreatment Sequence 1: TAK-041 40 mg/Placebo + AntipsychoticsTreatment Sequence 2: Placebo/TAK-041 40 mg + AntipsychoticsTreatment Sequence 3: TAK-041 160 mg/Placebo + AntipsychoticsTreatment Sequence 4: Placebo/TAK-041 160 mg + Antipsychotics
Started3497
Treated2486
Completed2486
Not completed1011
Withdrew: Withdrawal by subject1000
Withdrew: Reason not specified0011

Outcome measures

PrimaryChange From Baseline in the Brief Assessment of Cognition in Schizophrenia (BACS) Composite Score at Second Testing After TAK-041 Administration

BACS is a reliable and sensitive measure of cognitive function in schizophrenia. The BACS consists of items across six subtests: Verbal Memory, Digit Sequencing, Token Motor, Verbal Fluency, Symbol Coding, and Tower of London. The subtest scale scores were used to compute a composite BACS t-score of 50 (20) is the mean (standard deviation) of a relevant index population. Higher values indicate better performance. Bayesian normal linear model was used for analysis.

Time frame:
Baseline (Day -1) and Day 14
Reported as:
Mean · t-scale
Change From Baseline in the Brief Assessment of Cognition in Schizophrenia (BACS) Composite Score at Second Testing After TAK-041 Administration
t-scalePlaceboTAK-041 40 mgTAK-041 160 mg
Baseline29.72 ± 12.86727.35 ± 12.75327.89 ± 8.214
Day 142.28 ± 6.9635.35 ± 6.9441.31 ± 5.618
Statistical analysis
  • Placebo vs TAK-041 40 mg · Bayesian Normal Linear Model · p = 0.2079 (Bayesian method was used to calculate the posterior probability. High posterior probability of a difference between TAK-041 and placebo \>2.0.)
  • Placebo vs TAK-041 160 mg · Bayesian Normal Linear Model · p = 0.0633 (Bayesian method was used to calculate the posterior probability. High posterior probability of a difference between TAK-041 and placebo \>2.0.)
PrimaryBlood-Oxygen-Level-Dependent (BOLD) Signal in the Average Ventral Striatum (VS) Region of Interest (ROI) Activation in the Monetary Incentive Delay (MID) Reward Task at First Testing After TAK-041 Administration

Blood-oxygen-level-dependent imaging, or BOLD-contrast imaging, is a method used in functional magnetic resonance imaging (fMRI) to observe different areas of the brain or other organs, which are found to be active at any given time. The MID task is a reward anticipation paradigm that robustly engages the VS, a key area associated with coding incentive reward. Dysfunctional processing of reward information is associated with motivational impairments in schizophrenia. Motivational impairment is a key aspect of negative symptoms, and has been associated with reduced activity in the VS. Any change in BOLD signal that comes in fMRI is reported.

Time frame:
Day 1
Reported as:
Mean · BOLD signal
Blood-Oxygen-Level-Dependent (BOLD) Signal in the Average Ventral Striatum (VS) Region of Interest (ROI) Activation in the Monetary Incentive Delay (MID) Reward Task at First Testing After TAK-041 Administration
BOLD signalPlaceboTAK-041 40 mgTAK-041 160 mg
Blood-Oxygen-Level-Dependent (BOLD) Signal in the Average Ventral Striatum (VS) Region of Interest (ROI) Activation in the Monetary Incentive Delay (MID) Reward Task at First Testing After TAK-041 Administration0.23 ± 0.3960.23 ± 0.2020.03 ± 0.458
Statistical analysis
  • Placebo vs TAK-041 40 mg · Bayesian Normal Linear Model · p = 0.1706 (Bayesian method was used to calculate the posterior probability. High posterior probability of a difference between TAK-041 and placebo \>0.09.)
  • Placebo vs TAK-041 160 mg · Bayesian Normal Linear Model · p = 0.0373 (Bayesian method was used to calculate the posterior probability. High posterior probability of a difference between TAK-041 and placebo \>0.09.)
SecondaryPercentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
From the first dose of study drug up to 77 days after last dose of study drug (Up to Day 154)
Reported as:
Number · percentage of participants
Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)
percentage of participantsPlaceboTAK-041 40 mgTAK-041 160 mg
Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)57.171.453.3
SecondaryPercentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post Dose

Clinical Laboratory parameters included tests for chemistry, hematology and urinalysis. Markedly abnormal values during treatment period were categorized as: alanine aminotransferase (ALT)\>3.0 U/L\*upper limit of normal(ULN),albumin\<25 g/L\*lower limit of normal(LLN), alkaline phosphatase \>3.0 U/L\*ULN, aspartate aminotransferase \>3.0 U/L\*ULN, bilirubin \>34.2 umol/L\*ULN, calcium \<1.75 mmol/L, \>2.88 mmol/L, chloride \<75 mmol/L, \>126 mmol/L, creatinine \>177umol/L, gamma glutamyl transferase \>3 U/L\*ULN, glucose \<2.8 mmol/L, \>19.4 mmol/L, potassium\<3 mmol/L, \>6 mmol/L, sodium \<130 mmol/L, \>150 mmol/L,Urea \<130 mmol/L, erythrocytes \<0.8\*LLN \>1.2\*ULN, hematocrit \<0.8\*LLN, \>1.2\*ULN, hemoglobin \<0.8 g/L\*LLN, \>1.2 g/L\*ULN, leukocytes \<0.5 (10\^9/L)\*LLN, \>1.5 (10\^9/L)\*ULN, platelets \<75(10\^9/L), \>600(10\^9/L).

Time frame:
From the first dose of study drug up to 77 days after last dose of study drug (Up to Day 154)
Reported as:
Number · percentage of participants
Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post Dose
percentage of participantsPlaceboTAK-041 40 mgTAK-041 160 mg
Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post Dose000
SecondaryPercentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements At Least Once Post Dose

Vital signs included oral body temperature measurement, supine and standing blood pressure, respiration rate, and pulse. Pulse and blood pressure were measured after 5 minutes supine and again at 1 and 3 minutes after standing. The markedly abnormal value (MAV) criteria for vital signs included systolic blood pressure \< 85 mmHg, \> 180 mmHg; diastolic blood pressure \< 50 mmHg, \> 110 mmHg; pulse \< 50 beats/min, \> 120 beats/min; temperature \< 35.6 C \> 37.7 C.

Time frame:
From the first dose of study drug up to 77 days after last dose of study drug (Up to Day 154)
Reported as:
Number · percentage of participants
Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements At Least Once Post Dose
percentage of participantsPlaceboTAK-041 40 mgTAK-041 160 mg
<35.6 C006.7
>37.7 C4.800
SecondaryPercentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) at Least Once Post Dose

The markedly abnormal value (MAV) criteria for 12-lead ECG parameters included ECG Mean Heart Rate \< 50 beats/min, \> 120 beats/min; PR Interval, Aggregate \<= 80 msec, \>= 200 msec; QRS Duration, Aggregate \<= 80 msec, \>= 180 msec; QTcB Interval, Aggregate \<= 300 msec, \>= 500 msec OR (\>= 30 msec change from baseline and \>= 450 msec); QTcF Interval, Aggregate \<= 300 msec, \>= 500 msec OR (\>= 30 msec change from baseline and \>= 450 msec).

Time frame:
From the first dose of study drug up to 77 days after last dose of study drug (Up to Day 154)
Reported as:
Number · percentage of participants
Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) at Least Once Post Dose
percentage of participantsPlaceboTAK-041 40 mgTAK-041 160 mg
ECG Mean Heart Rate: <50 beats per minute006.7
PR Interval: >=200 milliseconds10.520.013.3
QRS Duration: <=80 milliseconds36.820.033.3
SecondaryNumber of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS)

Treatment-emergent suicidal ideation (SI) or suicidal behavior (SB) compared to baseline will be measured by an increase in suicidal ideation category (1-5 on the C-SSRS) or suicidal behavior category (6-10 on the C-SSRS) during treatment from the maximum suicidal ideation/behavior category at baseline, or any suicidal ideation/behavior during treatment if there is none at baseline. C-SSRS is used to assess whether participant experienced suicidal ideation (1: wish to be dead; 2: non-specific active suicidal thoughts; 3: active suicidal ideation with any methods (not plan) without intent to act; 4: active suicidal ideation with some intent to act, without specific plan; 5: active suicidal ideation with specific plan and intent) and suicidal behavior (6: actual attempt; 7: interrupted attempt; 8: aborted attempt; 9: preparatory acts or behavior; 10: suicidal behavior).

Time frame:
Baseline (Day -1) and Days 14, 35 and 77
Reported as:
Count of participants · Participants
Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS)
ParticipantsPlaceboTAK-041 40 mgTAK-041 160 mg
SI-Wish to be Dead, Day -1301
SI-Wish to be Dead, Day 14100
SI-Wish to be Dead, Day 77101
SB-Non-suicidal Self-injurious Behaviour, Day 77—10

Adverse events

Collected over From the first dose of study drug up to 77 days after last dose of study drug (Up to Day 154). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/21 (0%)0/21 (0%)12/21 (57.1%)
TAK-041 40 mg0/7 (0%)0/7 (0%)5/7 (71.4%)
TAK-041 160 mg0/15 (0%)0/15 (0%)8/15 (53.3%)
Most frequent other events
Showing 10 of 36
Most frequent other events
EventPlaceboTAK-041 40 mgTAK-041 160 mg
CoughRespiratory, thoracic and mediastinal disorders0/212/70/15
HeadacheNervous system disorders2/211/71/15
NasopharyngitisInfections and infestations3/211/70/15
Back PainMusculoskeletal and connective tissue disorders0/211/71/15
Lymphocyte Count DecreasedInvestigations0/211/70/15
Procedural HeadacheInjury, poisoning and procedural complications0/211/70/15
HypokalaemiaMetabolism and nutrition disorders0/211/70/15
FatigueGeneral disorders2/210/71/15
Upper Respiratory Tract InfectionInfections and infestations2/210/70/15
MyalgiaMusculoskeletal and connective tissue disorders2/210/70/15

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Treatment Sequence 1: TAK-041 40 mg/Placebo + AntipsychoticsTreatment Sequence 2: Placebo/TAK-041 40 mg + AntipsychoticsTreatment Sequence 3: TAK-041 160 mg/Placebo + AntipsychoticsTreatment Sequence 4: Placebo/TAK-041 160 mg + AntipsychoticsTotal
Mean42.0 ± 16.539.3 ± 16.146.8 ± 12.143.4 ± 9.643.8 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Sequence 1: TAK-041 40 mg/Placebo + AntipsychoticsTreatment Sequence 2: Placebo/TAK-041 40 mg + AntipsychoticsTreatment Sequence 3: TAK-041 160 mg/Placebo + AntipsychoticsTreatment Sequence 4: Placebo/TAK-041 160 mg + AntipsychoticsTotal
Female02226
Male327517
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment Sequence 1: TAK-041 40 mg/Placebo + AntipsychoticsTreatment Sequence 2: Placebo/TAK-041 40 mg + AntipsychoticsTreatment Sequence 3: TAK-041 160 mg/Placebo + AntipsychoticsTreatment Sequence 4: Placebo/TAK-041 160 mg + AntipsychoticsTotal
Hispanic or Latino00000
Not Hispanic or Latino349723
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment Sequence 1: TAK-041 40 mg/Placebo + AntipsychoticsTreatment Sequence 2: Placebo/TAK-041 40 mg + AntipsychoticsTreatment Sequence 3: TAK-041 160 mg/Placebo + AntipsychoticsTreatment Sequence 4: Placebo/TAK-041 160 mg + AntipsychoticsTotal
American Indian or Alaska Native00000
Asian00101
Native Hawaiian or Other Pacific Islander00000
Black or African American334616
White01405
More than one race00011
Unknown or Not Reported00000
08

Study locations

1 site
  • Kings College London
    London, SE58AF, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Sep 2019, 20 months.

Results were first posted in Feb 2021, 1 year 4 months after primary completion.

Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's 20 months is close to that.

Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2017
First posted
Oct 24, 2017
StartActual
Dec 21, 2017
Primary completionActual
Sep 11, 2019
CompletionActual
Nov 6, 2019
Results first posted
Feb 9, 2021
Last update
Mar 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03319953
Collaborators
Takeda
Responsible party
Sponsor
First posted
Oct 24, 2017
Start date
Dec 21, 2017
Primary completion
Sep 11, 2019
Completion
Nov 6, 2019
Results posted
Feb 9, 2021
Last update
Mar 19, 2021

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TAK-041

Start the discussion